Viewing Eye Care Network

Cornea

Latest News


CME Content


One of the most memorable patients ever to walk into the office of Sonal Tuli, MD, had a fishhook protruding from his eye, which he held open with his fingers. Dr. Tuli offers some pointers based on experience from cases like these.

The same photoactivation process used in collagen cross-linking for keratoconus can kill bacteria without the need for the oxygen responsible for the biomechanical effects, potentially pointing toward better treatments for keratitis, according to Olivier Richoz, MD, PhD.

Over the past few years, various diagnostics have been introduced to help clinicians identify inflammatory conditions on the ocular surface more readily and, therefore, provide treatment to patients earlier in their disease states.

2015 may be noted as a year of emergence for sustained-release drug delivery therapies for dry eye and glaucoma, according to Jonathan H. Talamo, MD, Boston.Cornea specialists have always appreciated the need to treat dry eye, “but it’s now becoming more and more appreciated and the importance of underlying dry eye and drying is so ubiquitous,” said Ernest W. Kornmehl, MD, Brookline, MA.

Ophthalmology Times is pleased to announce Amy Patel, MD, of Gavin Herbert Eye Institute, UC Irvine Health, Irvine, CA, as the winner of its 2015 Resident Writer’s Award Program, sponsored by Allergan. Dr. Patel’s winning entry is featured here.

Contact lens-assisted corneal crosslinking (CA-CXL) is a novel technique in which a riboflavin-soaked ultraviolet (UV) barrier-free soft contact lens is applied over the denuded cornea prior to UVA irradiation.

Contact lens-Assisted corneal crosslinking (CA-CXL) is a novel technique in which a riboflavin-soaked ultraviolet (UV) barrier-free soft contact lens is applied over the denuded cornea prior to UVA irradiation. It is used to allow CXL in eyes with a thin cornea and has been associated with good results, and can be done with a standard or accelerated CXL protocol.

Understanding of keratoconus and the resulting dramatic changes in management in recent years have given rise to treatment paradigms that would have been unrecognizable to ophthalmologists a generation ago. The new landscape features a wider range of treatment options, better diagnostic and monitoring tools, and better understanding of the underlying pathology of the disease.

Findings from a study undertaken at Dr Lovisolo’s practice indicate that in carefully-selected patients, a triple procedure, comprising Keraring implantation followed by accelerated CXL and topo-guided ablation can provide significant functional improvement in cases of progressive keratoconus.

An age-stratified analysis of endothelial cell count in diabetic and non-diabetic corneas found no statistically significant difference between the groups. Since diabetes may damage the inner layer of the cornea, other variables that affect cell health must also be evaluated.

Small incision lenticule extraction (SMILE), which has not yet been approved for refractive correction in the United States, may be less accurate and produce more irregular astigmatism than LASIK or PRK because of the imprecision resulting from the two incisions needed to create the lenticule. In addition, the technique for potential enhancements needs improvement. However, the treatment is promising and may stand the test of time as the technology advances.